Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

The primary hypothesis is that the CH505 TF chTrimer vaccine will expand B cell precursor lineages capable of ultimately producing autologous and heterologous Tier 2 broadly neutralizing antibodies (bnAbs). Participants receive CH505 TF chTrimer plus 3M-052-AF (at either a 3 mcg dose or a 5 mcg dose), with or without Alum, via two intramuscular injections administered five times throughout the study. Participants are evaluated for safety and immune responses through blood collection at specified timepoints throughout the study. Each participant has up to 18 months of scheduled clinic visits and a follow-up safety assessment 12 months after their final vaccination.